	US 12,454,569 B2
	Method of reducing glucose intolerance or insulin resistance in a patient in need thereof
Gokhan S. Hotamisligil, Wellesley, MA (US); and Haiming Cao, Bethesda, MD (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Jun. 26, 2023, as Appl. No. 18/341,404.
Application 18/341,404 is a continuation of application No. 17/102,329, filed on Nov. 23, 2020, granted, now 11,685,774.
Application 17/102,329 is a continuation of application No. 15/851,040, filed on Dec. 21, 2017, granted, now 10,882,901, issued on Jan. 5, 2021.
Application 15/851,040 is a continuation of application No. 15/093,508, filed on Apr. 7, 2016, granted, now 9,879,078, issued on Jan. 30, 2018.
Application 15/093,508 is a continuation of application No. 13/203,880, abandoned, previously published as PCT/US2010/026305, filed on Mar. 5, 2010.
Claims priority of provisional application 61/299,170, filed on Jan. 28, 2010.
Claims priority of provisional application 61/209,251, filed on Mar. 5, 2009.
Prior Publication US 2024/0209072 A1, Jun. 27, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01)]

14 Claims

1. A method of reducing glucose intolerance in a human having glucose intolerance comprising administering to the human an effective amount of an Adipocyte Protein 2 (aP2)-specific antibody that specifically binds to aP2 in blood or serum.